FindTrial
Sign In

Health-related quality of life predicts survival for patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization

Prospective observational study of health-related quality of life predicts survival for patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17012936
Enrollment
Unknown
Registered
2017-10-10
Start date
2011-07-01
Completion date
Unknown
Last updated
2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Case series:TACE treatment

Sponsors

Eastern Hepatobiliary Surgery Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
21 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years; 2. Presence of a single nodule of more than 50 mm in diameter, two to three tumor nodules, each measuring more than 30 mm in diameter, or more than three nodules; 3. No vascular invasion or extrahepatic metastasis; 4. Child–Pugh class A or B; 5. Good kidney function (a serum creatinine level 50 x 10^9/L and a prolonged prothrombin time of <5 s; 7. To be able to self-complete the questionnaires.

Exclusion criteria

Exclusion criteria: 1. coagulopathy; 2. with history of malignancy; 3. previous treatment of HCC; 4. cognitive impairment and no obstacles in language communication.

Design outcomes

Primary

MeasureTime frame
overall survival;—

Countries

China

Contacts

Public ContactGang Huang

Eastern Hepatobiliary Surgery Hospital

squaror@163.com+86 13918663457

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026